What Is Genetic Engineering: CRISPR, Gene Editing, and the Future of Medicine

Rewriting the Code of Life

For most of human history, altering the genetic makeup of organisms was the slow, indirect work of selective breeding — choosing the plants with the largest seeds or the animals with the calmest temperaments and breeding them together over generations, hoping that favorable traits would accumulate. The process worked, transforming wolves into dogs and wild grasses into wheat, but it was slow, imprecise, and constrained by what natural variation had to offer. Genetic engineering changed all of that. By providing tools to directly read, cut, and rewrite DNA with increasing precision and ease, molecular biology has given humanity the power to alter the blueprint of life itself, on timescales of weeks rather than generations.

Genetic engineering encompasses a broad range of techniques for modifying an organism's DNA. Early methods — restriction enzymes, recombinant DNA technology, gene cloning — developed from the 1970s onward and enabled the production of therapeutic proteins, the creation of genetically modified crops, and the explosion of molecular biology as a research discipline. The most recent and transformative addition to the genetic engineering toolkit is CRISPR-Cas9, a system adapted from a bacterial immune mechanism that allows scientists to make precise, targeted edits to DNA sequences in virtually any organism, quickly and cheaply enough to be used routinely in laboratories around the world.

The Foundation: Restriction Enzymes and Recombinant DNA

Genetic engineering became possible in the 1970s with the discovery and exploitation of restriction enzymes — bacterial proteins that cut DNA at specific short recognition sequences. By cutting both a gene of interest and a carrier DNA molecule (a plasmid or viral vector) with the same restriction enzyme, scientists could produce compatible cut ends that could be joined together using another enzyme, DNA ligase. The resulting recombinant DNA molecule contained sequences from two different sources — for example, a human insulin gene inserted into a bacterial plasmid.

Introducing recombinant plasmids into bacteria, a process called transformation, allowed bacteria to serve as living factories, expressing and producing human proteins in large quantities. This approach enabled the production of recombinant human insulin (approved 1982), erythropoietin, growth hormone, blood clotting factors, and hundreds of other therapeutic proteins that would otherwise require extraction from human blood, animal tissue, or cadavers at great expense and with significant contamination risk. Recombinant DNA technology was the foundation of the biotechnology industry and produced the first generation of genetic engineering applications in medicine.

Transgenic Organisms and Gene Targeting

Beyond inserting genes into bacteria, genetic engineers developed methods to create transgenic organisms — animals and plants that stably carry foreign genes in their chromosomes, passed to all offspring. Transgenic mice became essential research tools from the 1980s: by inserting human disease genes into mice, researchers could model human diseases in laboratory animals and test therapeutic interventions. Gene knockout mice, in which specific genes were disabled, revealed gene functions and provided models for human genetic diseases.

Creating targeted knockouts required homologous recombination — a natural DNA repair mechanism that can replace a chromosomal sequence with an engineered substitute when the substitute carries sequences matching the target region. This technique worked efficiently in mouse embryonic stem cells, enabling the creation of knock-out and knock-in mouse lines that transformed biomedical research. But it was slow, expensive, and inefficient — the homologous recombination event was rare and had to be selected for among many non-targeted events. The need for faster, more efficient, more broadly applicable gene editing drove the development of programmable nucleases.

Before CRISPR: Zinc Fingers and TALENs

The first generation of programmable nucleases — enzymes that could be engineered to cut DNA at user-specified locations — were zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). Both systems worked by linking a DNA-binding domain (which could be engineered to recognize specific DNA sequences) to the FokI nuclease, which cuts DNA when dimerized. Creating a cut at a specific genomic locus triggers the cell's DNA repair machinery: if a repair template is provided, the cell uses homologous recombination to incorporate it, enabling precise edits.

ZFNs and TALENs demonstrated the proof of concept for targeted genome editing and produced the first clinical trials of gene-edited cells. But both required engineering a new protein for each new target sequence — a time-consuming and technically demanding process. TALENs were simpler to engineer than ZFNs but still required weeks of protein engineering for each target. The field needed a system where the targeting specificity was encoded in a nucleic acid rather than a protein — something much easier to design and synthesize.

CRISPR-Cas9: The Game Changer

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) was discovered in bacteria as part of an adaptive immune system. Bacteria that survive viral infection incorporate short sequences from the viral genome into their own DNA in the CRISPR arrays; these sequences serve as memory of past infections. When the bacterium encounters the same virus again, it transcribes the stored sequences into CRISPR RNA (crRNA), which guides a nuclease protein (Cas — CRISPR-associated protein) to the matching viral DNA sequence, cutting it and destroying the virus.

The landmark 2012 paper by Jennifer Doudna, Emmanuelle Charpentier, and colleagues showed that the CRISPR-Cas9 system from the bacterium Streptococcus pyogenes could be simplified and reprogrammed in vitro: by designing a single guide RNA (sgRNA) containing a 20-nucleotide sequence complementary to any target DNA sequence (adjacent to a short PAM sequence), researchers could direct Cas9 to cut that specific location in any genome. This was transformative: instead of engineering a new protein for each target, researchers could simply synthesize a new sgRNA — a process taking hours rather than weeks. CRISPR-Cas9 rapidly became the dominant genome editing tool across biology. Doudna and Charpentier were awarded the 2020 Nobel Prize in Chemistry for this work.

CRISPR in Medicine: From Bench to Clinic

CRISPR is advancing into clinical medicine on multiple fronts. The most mature applications involve ex vivo editing: removing cells from a patient, editing them outside the body, and returning them. The first approved CRISPR therapies — Casgevy and Lyfgenia, both approved in late 2023 — treat sickle cell disease and beta-thalassemia by editing patients' hematopoietic stem cells to reactivate fetal hemoglobin production, compensating for the defective adult hemoglobin. These treatments represent a functional cure for diseases that previously required lifelong management or bone marrow transplantation.

In vivo CRISPR delivery — editing DNA inside the living body — is more challenging but is advancing. Transthyretin amyloidosis, a fatal condition caused by misfolded protein accumulation, is being treated with in vivo CRISPR delivered to the liver via lipid nanoparticles. Early trials show striking reductions in the disease-causing protein. Cancer immunotherapy, infectious diseases (including HIV), and inherited conditions affecting the eye, ear, and brain are all being targeted by CRISPR-based approaches in clinical trials. CRISPR base editing and prime editing — newer variants that change individual DNA bases without cutting both strands — offer even greater precision with reduced risk of unintended off-target effects.

CRISPR in Agriculture and the Ethics of Gene Editing

CRISPR is also transforming agriculture. Unlike earlier GMO approaches that typically inserted foreign genes from different species, CRISPR editing can make targeted changes within a species' own genome — changes that could also arise through natural mutation or conventional breeding. This distinction has influenced regulatory treatment: the US Department of Agriculture has determined that many CRISPR-edited crops do not require the same regulatory review as traditional GMOs. CRISPR-developed crops already approved or in development include disease-resistant wheat, drought-tolerant corn, browning-resistant mushrooms, and cattle with heat-resistant traits.

The power of CRISPR raises profound ethical questions that society is only beginning to grapple with. The editing of human germline cells — embryos, eggs, or sperm — would produce heritable changes passed to all future generations, a fundamentally different category from somatic cell editing. The 2018 announcement by He Jiankui that he had created the first CRISPR-edited babies (resistant to HIV through CCR5 deletion) was met with near-universal scientific and ethical condemnation, not only because of safety and consent violations but because of the unilateral nature of a decision with implications for all of humanity. International scientific bodies have called for a moratorium on heritable human genome editing until safety, efficacy, and governance frameworks are established — a conversation that is ongoing and touches on the deepest questions about the future of the human species.